Illumina, Inc. Hits New 52-Week High at USD 165.37

Illumina, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 165.37 on May 29, 2026. This achievement underscores the company's robust performance, with a remarkable one-year gain of 52.69%, significantly outpacing the S&P 500's performance of 28.21% during the same period. With a market capitalization of USD 22,890 million, Illumina operates as a mid-cap company, reflecting its substantial presence in the industry. The stock's price-to-earnings (P/E) ratio stands at 36.00, indicating investor confidence in its earnings potential. Additionally, the company maintains a low debt-to-equity ratio of 0.16, suggesting a solid financial foundation. Illumina's return on equity is an impressive 23.44%, highlighting its efficiency in generating profits from shareholders' equity. However, the company does not offer a dividend yield, which is currently at 0.00%. The stock's previous 52-week low was recorded at USD 78.79, marking a significant recovery and growth trajectory for the company.